Japan’s Taiho Pharmaceutical: An Oral Chemotherapy Pioneer
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho…
Tagged with Japan
Eisai Targeting Global Leadership in Neurology & Oncology…
Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of…
Japan: The Latest Therapeutic Applications in Induced Pluripotent…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive…
UK-Japan FTA: Banishing UK Pharma’s Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which…
Asia-Pacific Pharma Partnerships News September 2020
The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and…
Japan Market Entry: Opportunities & Challenges
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park, gives an insider’s take on the opportunities and challenges for pharma…
Ken-ichiro Hata – Representative Director &…
Dr Ken-ichiro Hata, representative director and chairperson of Japan’s Forum for Innovative Regenerative Medicine (FIRM) outlines the…
How Chugai Became Japan’s Top Pharma Company
In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven by strong performance in recent years both from the company’s own…
Japanese Pharma’s Skyrocketing US Footprint
Following PharmaBoardroom’s recent interview with Ivan Cheung, chairman of Eisai’s US affiliate and president of Eisai’s global neurology…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Ryu Ogawa – CEO & Satoshi Tamaki – CSO, Molcure,…
Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency…
Maintaining Open Innovation in Our ‘New Normal’ Through…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while…
